Skip to main content
Contact Us
Subscribe
E-Edition
77°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Horizon Therapeutics
(NQ:
HZNP
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 5, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Horizon Therapeutics
< Previous
1
2
3
4
5
6
7
8
Next >
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration
April 14, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc to Release First-Quarter 2023 Financial Results on May 3, 2023
April 14, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
April 10, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc Named to the 2023 Fortune 100 Best Companies to Work For List
April 04, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
March 16, 2023
From
Horizon Therapeutics plc
Via
Business Wire
New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
March 14, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)
March 12, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc - Rule 2.12 Announcement
March 01, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results
March 01, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc Opens Applications for #RAREis Global Advocate Grant Program
February 28, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc Announces Voting Results from Special Shareholder Meetings
February 24, 2023
From
Horizon Therapeutics plc
Via
Business Wire
New Data Suggest UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childhood Vaccines
February 23, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023
January 30, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Rule 15 (c) Announcement – Horizon Therapeutics plc
January 27, 2023
From
Horizon Therapeutics plc
Via
Business Wire
HORIZON THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limited Company - HZNP
January 25, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Rule 17 (b) Announcement – Horizon Therapeutics plc
January 23, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Rule 17 (a) Announcement – Horizon Therapeutics plc
January 23, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient Populations
January 18, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Rule 2.12 Announcement – Horizon Therapeutics plc
January 12, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
January 06, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
January 04, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
January 04, 2023
From
Horizon Therapeutics plc
Via
Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
January 03, 2023
From
Horizon Therapeutics plc
Via
Business Wire
UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
December 20, 2022
From
Horizon Therapeutics plc
Via
Business Wire
HORIZON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limited Company - HZNP
December 13, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Form 8.1 Opening Position Disclosure (Horizon Therapeutics plc)
December 13, 2022
From
Horizon Therapeutics plc
Via
Business Wire
HZNP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Horizon Therapeutics plc Is Fair to Shareholders
December 12, 2022
From
Halper Sadeh LLC
Via
Business Wire
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc
December 12, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
December 08, 2022
From
Horizon Therapeutics plc
Via
Business Wire
Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer
November 29, 2022
From
Horizon Therapeutics plc
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.